PROTEONOMIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-10-05: Form 8-K; Period of report 2012-10-05; Description 3.03 Material Modification to Rights of Security Holders; Details 3.03.
- 2012-09-19: Form 8-K; Period of report 2012-09-19; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2012-08-13: Form 8-K; Period of report 2012-08-13; Description 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review; Details 4.02.
- 2012-08-09: Form 8-K; Period of report 2012-08-02; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-10-05 | 8-K | 2012-10-05 | 3.03 Material Modification to Rights of Security Holders | 3.03 The following lists sales of unregistered securities exceeding 5% of the total issued and outstanding common stock since the filing of the Form 10-Q for the period ending June 30, 2012. | f8kunrergisteredsalesdisclos.htm |
| 2012-09-19 | 8-K | 2012-09-19 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On September 12, 2012, the Company entered into an agreement with the University of Medicine & Dentistry of New Jersey to conduct a clinical trial of the Company’s UMK-121, a combination of two FDA approved drugs being used as a hopefully new therapy for, in this instance, end stage liver disease (ESLD). | form8k914121.htm |
| 2012-08-13 | 8-K | 2012-08-13 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 On August 7, 2012, the board of directors of Proteonomix, Inc. (the “Company”) determined that the Company’s previously issued interim consolidated financial statement for the three months ended March 31, 2012 should no longer be relied upon due to an anticipated restatement of the derivative liability. | form8k08082012.htm |
| 2012-08-09 | 8-K | 2012-08-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 2, 2012, Michael Cohen, Chairman of the Board of Directors of Proteonomix, Inc. (the “Company”) who serves also as the Company’s Chief Executive Officer resigned as the Company’s Chief Financial Officer and Treasurer. | v320818_8k.htm |
| 2012-06-18 | 8-K/A | 2012-06-18 | 4.01 Changes in Registrant's Certifying Accountant | f8ka6182012final.htm | |
| 2012-06-12 | 8-K | 2012-06-12 | 4.01 Changes in Registrant's Certifying Accountant | f8k6122012final.htm | |
| 2012-06-07 | 8-K | 2012-06-07 | 8.01 Other Events | 8.01 HAWTHORNE, N.J. (June 7, 2012) – Proteonomix, Inc. (OTC/BB: PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announces the oral presentation by Chief Scientific Officer Ian McNiece, Ph.D., of research related to the Company’s UMK-121 technology today at the International Society for Cellular Therapy (ISCT) 18th Annual Meeting underway in Seattle. | f8k06072012.htm |
| 2012-05-25 | 8-K | 2012-05-21 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) On May 21, 2012, Proteonomix, Inc. (the “Registrant” or the “Company”) was notified by Demetrius & Company, L.L.C. (“Demetrius”) that they have resigned as the Registrant’s independent registered public accounting firm. | v314654_8k.htm |
| 2012-05-14 | 8-K | 2012-05-08 | 4.01 Changes in Registrant's Certifying Accountant | v313284_8k.htm | |
| 2012-05-02 | 8-K | 2012-05-02 | 8.01 Other Events | 8.01 On April 24, 2012, the Registrant received a subpoena from the U.S. Securities and Exchange Commission for a number of documents and correspondence pursuant to a formal investigation of the Registrant. | f8k025212final.htm |
| 2012-04-27 | 8-K | 2012-04-27 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) On April 24, 2012, Proteonomix, Inc. (the “Registrant” or the “Company”) was notified by KBL, LLP (“KBL”) that they have resigned as the Registrant’s independent registered public accounting firm. | f8k042612v4.htm |
| 2012-04-11 | 8-K | 2012-04-11 | 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.02 On April 10, 2012, the University of Miami (“University”) terminated the Research Agreement (“Agreement”) between the University and the Registrant, Proteonomix, Inc. (the “Company”) by delivering written notice of the termination to the Company. 8.01 The Company has scheduled meetings aimed at finding another institution to conduct the Phase 1 Clinical Trial of UMK-121. | f8k041112.htm |
| 2012-03-13 | 8-K | 2012-03-13 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 On March 5, 2012, Proteonomix, Inc. (the “Registrant”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the purchasers identified therein (collectively, the “Purchasers”) providing for the issuance and sale by the Company to the Purchasers of an aggregate of approximately 3,804 shares of the Registrant’s Series E Convertible Preferred Stock (the “Preferred Shares”), with each Preferred Share initially convertible into approximately 235 shares of the Registrant’s Common Stock (the “Conversion Shares”) and three series of warrants, the Series A Warrants, the Series B Warrants and the Series C Warrants, to purchase up to an aggregate of 2,685,873 shares of the Company’s Common Stock (collectively, the “Warrants” and the shares issuable upon exercise of the Warrants, collectively, the “Warrant Shares”), for proceeds to the Company of $3.8 million. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.02 in its entirety. | form8k03132012final.htm |
| 2012-02-10 | 8-K | 2012-02-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | form8k02102012.htm |
| 2012-02-03 | 8-K | 2012-02-03 | 8.01 Other Events | 8.01 On February 2, 2012, Proteoderm, Inc. (the “Company”), a controlled subsidiary of Proteonomix, Inc. (the “Registrant”) hired Jaci Mandil, of Livingston, New Jersey, as its Chief Executive and Operating Officer. | f8k02032012.htm |
| 2012-02-02 | 8-K | 2012-02-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | form8k02022012.htm |
| 2012-02-01 | 8-K | 2012-02-01 | 8.01 Other Events | 8.01 On February 1, 2012, Proteonomix, Inc. (the “Issuer”) today made the attached presentation at the Merriman Capital Investor Summit 2012 at the Intercontinental Hotel in New York City. | merrimanpresentation2112.htm |
| 2012-01-06 | 8-K | 2012-01-06 | 3.03 Material Modification to Rights of Security Holders | 3.03 On December 29, 2011, The Series A1 and Series B Preferred Stock classes were amended by filing with the Delaware Secretary of State’s Office Amended Certificate of Designation, Preferences and Rights of Preferred Stock of Proteonomix, Inc. (See Exhibit 3.11 filed herewith)(“Amended Designation”). | designationofpreferred10612.htm |
| 2012-01-05 | 8-K | 2012-01-04 | 8.01 Other Events | 8.01 MOUNTAINSIDE, NJ, January 4, 2012-- PROTEONOMIX, INC. | prot010420128k.htm |
| 2011-12-28 | 8-K | 2011-12-28 | 8.01 Other Events | 8.01 MOUNTAINSIDE, NJ- December 27, 2011-- PROTEONOMIX, INC. | prot122820118k.htm |
| 2011-12-09 | 8-K | 2011-12-09 | 8.01 Other Events | 8.01 MOUNTAINSIDE, NJ--(Dec 7, 2011) - Proteonomix, Inc. (OTCBB: PROT) sends letter to its shareholders. | prot120920118k.htm |
| 2011-11-22 | 8-K | 2011-11-22 | 8.01 Other Events | 8.01 MOUNTAINSIDE, NJ, November 21, 2011 -- PROTEONOMIX, INC. | prot112120118k.htm |
| 2011-11-15 | 8-K | 2011-09-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 15, 2011, Proteonomix, Inc. (the “Issuer”) today entered into an agreement with The University of Miami (the “University”), a premier educational institution, to conduct a FDA human clinical trial, in patients afflicted with End Stage Liver Disease (“ESLD”), of the Issuer’s UMK-121 Biopharmaceutical Stem Cell Technology (“UMK-121”) which is a proprietary technology based upon existing FDA approved drugs. | f8k111511.htm |
| 2011-11-14 | 8-K | 2011-11-14 | 8.01 Other Events | 8.01 Proteonomix, Inc. (PROT) Announces that its Subsidiary Proteoderm, Inc. has Received the Approval of its Application for INCI Registration of its Matrix NC-138 by the Cosmetic Ingredient Review Panel and is Now Able to Commercialize it Product in the USA. | prot11142011.htm |
| 2011-10-21 | 8-K | 2011-10-21 | 8.01 Other Events | 8.01 MOUNTAINSIDE, NJ--October 19, 2011-- PROTEONOMIX, INC. | prot10192011.htm |
| 2011-10-18 | 8-K | 2011-10-18 | 8.01 Other Events | prot10182011.htm | |
| 2011-09-29 | 8-K | 2011-09-29 | 8.01 Other Events | prot09282011.htm | |
| 2011-09-07 | 8-K | 2011-09-07 | 8.01 Other Events | prot090720118k.htm | |
| 2011-06-17 | 8-K | 2011-06-17 | 8.01 Other Events | prot0617118k.htm | |
| 2011-04-08 | 8-K | 2011-04-08 | 8.01 Other Events | prot0407118k.htm | |
| 2011-03-11 | 8-K | 2011-03-11 | 8.01 Other Events | prot0311118k.htm | |
| 2011-03-08 | 8-K | 2011-03-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 2, 2011, Proteonomix, Inc. (the “Issuer”) entered into an agreement with The Cohen McNiece Foundation, Inc. (the “Foundation”), a Florida not-for-profit corporation, to exclusively develop and license the Foundation’s UMK-121 Mobilization of Bone marrow Stem Cell technology (“UMK-121”) which is a proprietary technology based upon existing FDA approved drugs. | prot0308118k.htm |
| 2010-11-12 | 8-K | 2010-11-11 | 8.01 Other Events | prot1112108k.htm | |
| 2010-10-12 | 8-K | 2010-10-08 | 8.01 Other Events | prot1011108k.htm | |
| 2010-10-07 | 8-K | 2010-08-26 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | prot1007108k.htm | |
| 2010-08-26 | 8-K | 2010-08-26 | 8.01 Other Events | prot0825108k.htm | |
| 2010-08-19 | 8-K | 2010-08-18 | 8.01 Other Events | prot08018108k.htm | |
| 2010-08-16 | 8-K | 2010-08-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 On August 10, 2010, the Registrant entered into an agreement with a group of investors that will create a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). | prot0816108k.htm |
| 2010-08-05 | 8-K | 2010-08-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | prot0805108k.htm | |
| 2010-08-04 | 8-K | 2010-06-01 | 8.01 Other Events | prot0803108k.htm | |
| 2010-06-08 | 8-K | 2010-06-07 | 8.01 Other Events | 8.01 Proteonomix, Inc. (PROT) Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Agency. | prot0608108k.htm |
| 2010-06-02 | 8-K | 2010-06-01 | 8.01 Other Events | prot0601108k.htm | |
| 2010-06-01 | 8-K | 2010-06-01 | 8.01 Other Events | 8.01 Proteoderm, Inc. a Wholly Owned Subsidiary of Proteonomix, Inc. (PROT) Announces New Product Development. | prot052820108k.htm |
| 2010-05-26 | 8-K | 2010-05-24 | 8.01 Other Events | prot052420108k.htm | |
| 2010-05-05 | 8-K | 2010-02-25 | 8.01 Other Events | 8.01 Proteonomix, Inc. (PROT) Announces that it has Licensed Stromal Cell Technology for Potential Therapeutic use in the Regrowth of Damaged Cardiac Cells after a Heart Attack. | prot0504108k.htm |
| 2010-02-26 | 8-K | 2010-02-25 | 8.01 Other Events | prot0225108k.htm | |
| 2010-02-24 | 8-K/A | 2010-02-24 | 8.01 Other Events | prot0224108ka.htm | |
| 2010-02-24 | 8-K | 2010-02-24 | 8.01 Other Events | prot0212108k.htm | |
| 2010-02-23 | 8-K | 2010-02-23 | 8.01 Other Events | prot0222108k.htm | |
| 2010-02-18 | 8-K | 2010-02-18 | 8.01 Other Events | prot0218108k.htm | |
| 2010-02-02 | 8-K | 2009-08-19 | 8.01 Other Events | prot0201108k.htm | |
| 2010-01-25 | 8-K | 2010-01-25 | 8.01 Other Events | prot0125108k.htm | |
| 2009-12-30 | 8-K | 2009-12-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On December 29, 2009, Joel Pensley, a director of the Registrant, resigned from the Board of Directors for health reasons. 8.01 MOUNTAINSIDE, NJ - December 29, 2009 - Proteonomix, Inc. (PROT: Other OTC) announces that Joel Pensley as resigned as secretary, director and general counsel and Roger Fidler has joined the Company as director and general counsel; and Steven Byle, presently a director, has assumed the role of secretary. | prot1230098k.htm |
| 2009-08-19 | 8-K | 2009-08-19 | 8.01 Other Events | prot0819098k.htm |